A Phase 2/3 interventional study of Virtual Reality Exposure Therapy in Phobic Disorders, sponsored by VU University of Amsterdam. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-13.
Sponsored by VU University of Amsterdam · Phase 2/3, Interventional, and Treatment
Procedurally Virtual reality exposure therapy (VRET) is quite similar to models of extinction of conditioned fears. Recent advances in animal research have identified pharmacological agents that appear to both accelerate and consolidate extinction learning. One of these cognitive enhancers is Yohimbine. An interesting finding in animal literature is that the administration of Yohimbine during extinction trials accelerates fear reduction and may convert ineffective exposures in to successful ones. It is thought that the mechanism of enhanced emotional memory is through elevated norepinephrine in the prefrontal cortex. Therefore, we propose to extend these studies by combining VRET with Yohimbine. In this pilot study with a between groups design 20 participants with a fear of flying will be treated with VRET plus Yohimbine or VRET plus placebo. This between groups design was chosen to further characterize the differential within and between trial extinction. Outcome will be measured by self-report, behavioral, and psychophysiological assessments at pre- and post-treatment. In addition, we will examine extinction parameters during exposures.
135 studies on the registry are indexed under Phobic Disorders; 16 are open to participants now.
This study's enrollment of 67 is close to the median of 68 across 122 interventional studies indexed under Phobic Disorders.
Browse Phobic Disorders studies →VU University of Amsterdam is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Virtual Reality Exposure Therapy will be combined with the administration of yohimbine hydrochloride
Behavioral: Virtual Reality Exposure Therapy
Virtual Reality Exposure Therapy will be combined with an inactive placebo pill (Albochin).
Behavioral: Virtual Reality Exposure Therapy
Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
Flight Anxiety Situations Questionnaire (self-report); Flight Anxiety Modality Questionnaire (self-report)
Time frame: Assessed at pre- and post-treatment and 9-12 months follow-up
Severity of Anxiety Symptoms (Beck Anxiety Inventory) Anxiety Sensitivity (Anxiety Sensitivity Inventory)
Time frame: Assessed at pre- and post-treatment and 9-12 months follow-up
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VU University of Amsterdam